Gain Therapeutics (NASDAQ:GANX) stock is on the move Wednesday as investors react to updated clinical trial news from the company.
According to a press release from Gain Therapeutics, the company has started dosing the first two subjects in its Phase 1 clinical trial. This clinical trial covers GT-02287, which is the company’s lead candidate for the treatment of GBA1 Parkinson’s disease.
Gain Therapeutics has high hopes for GT-02287 based on preclinical data. It has shown potential for being able to restore functions of lysosomal enzyme glucocerebrosidase. These becoming misfolded is the most common genetic risk factor for Parkinson’s disease.
Matthias Alder, CEO of Gain Therapeutics, said this about the news:
“Initiating first-in-human dosing with GT-02287 is an important milestone for Gain as we enter a new era as a clinical-stage company. This represents another major step forward toward providing a treatment for Parkinson’s patients and their families impacted by this devastating disease.”
Investors wanting more information about the treatment will have to wait until the trial’s results come in. The company expects to complete Phase 1 of the study in the first half of 2024.
GANX Stock Movement on Wednesday
GANX stock isn’t seeing much in the way of trading activity on Wednesday, but its shares have already been on a wild ride. The company’s stock saw a major drop during pre-market hours, going as low as 60%. However, its shares are currently up slightly as of Wednesday morning.
Investors that are looking for even more of the most recent stock market stories are going to want to stick around!
We are offering up all of the latest stock market news that traders need to know about on Wednesday! A few examples include why shares of PodcastOne (NASDAQ:PODC) and Sonendo (NYSE:SONX) are up, as well as the biggest pre-market stock movers this morning. All of that news is ready to go at the links below!
More Stock Market News for Wednesday
- Why Is PodcastOne (PODC) Stock Up Today?
- Why Is Sonendo (SONX) Stock Up 38% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risk.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
